Current and Emerging Prognostic Biomarkers in Endometrial Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 May 9

PMID 35530346

Authors

Kelechi Njoku

Chloe E Barr

Emma J Crosbie

Affiliations

Soon will be listed here.

Abstract

Endometrial cancer is the most common gynaecological malignancy in high income countries and its incidence is rising. Whilst most women with endometrial cancer are diagnosed with highly curable disease and have good outcomes, a significant minority present with adverse clinico-pathological characteristics that herald a poor prognosis. Prognostic biomarkers that reliably select those at greatest risk of disease recurrence and death can guide management strategies to ensure that patients receive appropriate evidence-based and personalised care. The Cancer Genome Atlas substantially advanced our understanding of the molecular diversity of endometrial cancer and informed the development of simplified, pragmatic and cost-effective classifiers with prognostic implications and potential for clinical translation. Several blood-based biomarkers including proteins, metabolites, circulating tumour cells, circulating tumour DNA and inflammatory parameters have also shown promise for endometrial cancer risk assessment. This review provides an update on the established and emerging prognostic biomarkers in endometrial cancer.

Citing Articles

Immunohistochemistry as a reliable predictor of remission in patients with endometrial cancer: Establishment and validation of a machine learning model.

Wang R, Wang J, Wu Y, Zhu A, Li X, Wang J Oncol Lett. 2024; 29(1):59.

PMID: 39606567 PMC: 11599912. DOI: 10.3892/ol.2024.14805.

Minimally Invasive and Emerging Diagnostic Approaches in Endometrial Cancer: Epigenetic Insights and the Promise of DNA Methylation.

Porcaro F, Paolucci A, Porcaro P, Cardinale G, Romitelli A, Cozzolino D Diagnostics (Basel). 2024; 14(22).

PMID: 39594241 PMC: 11592808. DOI: 10.3390/diagnostics14222575.

Prognostic and clinicopathological role of prognostic nutritional index (PNI) in endometrial cancer: A meta-analysis.

Mao S, Zhang Z, Li Y Heliyon. 2024; 10(15):e35211.

PMID: 39157381 PMC: 11328061. DOI: 10.1016/j.heliyon.2024.e35211.

A 10-Year Retrospective Cohort Study of Endometrial Cancer Outcomes and Associations with Lymphovascular Invasion: A Single-Center Study from Germany.

Nienhaus A, Rajakulendran R, Bernad E Diagnostics (Basel). 2024; 14(15).

PMID: 39125562 PMC: 11311640. DOI: 10.3390/diagnostics14151686.

Our current understanding of the biological impact of endometrial cancer mtDNA genome mutations and their potential use as a biomarker.

Khadka P, Young C, Sachidanandam R, Brard L, Young M Front Oncol. 2024; 14:1394699.

PMID: 38993645 PMC: 11236604. DOI: 10.3389/fonc.2024.1394699.

References

Slawinski C, Barriuso J, Guo H, Renehan A . Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence. Clin Oncol (R Coll Radiol). 2020; 32(9):591-608. DOI: 10.1016/j.clon.2020.05.004. View

Thomas S, Hussein Y, Bandyopadhyay S, Cote M, Hassan O, Abdulfatah E . Interobserver Variability in the Diagnosis of Uterine High-Grade Endometrioid Carcinoma. Arch Pathol Lab Med. 2016; 140(8):836-43. PMC: 5656271. DOI: 10.5858/arpa.2015-0220-OA. View

Pergialiotis V, Oikonomou M, Damaskou V, Kalantzis D, Chrelias C, Tsantes A . Platelet to lymphocyte and neutrophil to lymphocyte ratio as predictive indices of endometrial carcinoma: Findings from a retrospective series of patients and meta-analysis. J Gynecol Obstet Hum Reprod. 2018; 47(10):511-516. DOI: 10.1016/j.jogoh.2018.08.016. View

Setiawan V, Yang H, Pike M, McCann S, Yu H, Xiang Y . Type I and II endometrial cancers: have they different risk factors?. J Clin Oncol. 2013; 31(20):2607-18. PMC: 3699726. DOI: 10.1200/JCO.2012.48.2596. View

Vermij L, Smit V, Nout R, Bosse T . Incorporation of molecular characteristics into endometrial cancer management. Histopathology. 2019; 76(1):52-63. PMC: 6972558. DOI: 10.1111/his.14015. View

Jiang T, Huang L, Zhang S . Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. BMC Cancer. 2015; 15:396. PMC: 4438478. DOI: 10.1186/s12885-015-1260-7. View

Jolly S, Vargas C, Kumar T, Weiner S, Brabbins D, Chen P . The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol. 2006; 103(1):87-93. DOI: 10.1016/j.ygyno.2006.01.038. View

Arem H, Park Y, Pelser C, Ballard-Barbash R, Irwin M, Hollenbeck A . Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. J Natl Cancer Inst. 2013; 105(5):342-9. PMC: 3589256. DOI: 10.1093/jnci/djs530. View

Bokhman J . Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. DOI: 10.1016/0090-8258(83)90111-7. View

10.

Audet-Delage Y, Villeneuve L, Gregoire J, Plante M, Guillemette C . Identification of Metabolomic Biomarkers for Endometrial Cancer and Its Recurrence after Surgery in Postmenopausal Women. Front Endocrinol (Lausanne). 2018; 9:87. PMC: 5857535. DOI: 10.3389/fendo.2018.00087. View

11.

Acikgoz A, Cakmak B, Tuten A, Oncul M, Eskalen S, Demirkiran F . Can preoperative neutrophil to lymphocyte and platelet to lymphocyte ratios predict cervical stromal involvement in endometrioid endometrial adenocarcinoma?. Eur J Gynaecol Oncol. 2018; 38(1):20-24. View

12.

Talhouk A, McConechy M, Leung S, Yang W, Lum A, Senz J . Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123(5):802-813. DOI: 10.1002/cncr.30496. View

13.

Kemik P, Saatli B, Yildirim N, Kemik V, Deveci B, Terek M . Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol. 2015; 140(1):64-9. DOI: 10.1016/j.ygyno.2015.11.020. View

14.

Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Kato K, Sakamoto T . Pretreatment Neutrophil-to-Lymphocyte Ratio Was a Predictor of Lymph Node Metastasis in Endometrial Cancer Patients. Oncology. 2019; 96(5):259-267. DOI: 10.1159/000497184. View

15.

Reijnen C, Visser N, Kasius J, Boll D, Geomini P, Ngo H . Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study. J Gynecol Oncol. 2019; 30(5):e70. PMC: 6658593. DOI: 10.3802/jgo.2019.30.e70. View

16.

Cicchillitti L, Corrado G, De Angeli M, Mancini E, Baiocco E, Patrizi L . Circulating cell-free DNA content as blood based biomarker in endometrial cancer. Oncotarget. 2018; 8(70):115230-115243. PMC: 5777767. DOI: 10.18632/oncotarget.23247. View

17.

Makker V, MacKay H, Ray-Coquard I, Levine D, Westin S, Aoki D . Endometrial cancer. Nat Rev Dis Primers. 2021; 7(1):88. PMC: 9421940. DOI: 10.1038/s41572-021-00324-8. View

18.

de Boer S, Wortman B, Bosse T, Powell M, Singh N, Hollema H . Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann Oncol. 2017; 29(2):424-430. PMC: 5834053. DOI: 10.1093/annonc/mdx753. View

19.

Cusano E, Myers V, Samant R, Sudai T, Keller A, Le T . Prognostic Significance of Lymphovascular Space Invasion in the Absence of Lymph Node Metastases in Early-Stage Endometrial Cancer. Int J Gynecol Cancer. 2018; 28(5):890-894. DOI: 10.1097/IGC.0000000000001229. View

20.

Ni L, Tao J, Xu J, Yuan X, Long Y, Yu N . Prognostic values of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2019; 301(1):251-261. PMC: 7028808. DOI: 10.1007/s00404-019-05372-w. View